R. Jenkins

Molecular Biology · Journal of Clinical Oncology · 2000–2018

A researcher in the Science corpus: 15 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 129 citations into it
• Cancer Research — 78 citations into it
• Genetics — 56 citations into it

Whom R. Jenkins trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. H. Ohgaki
2. Manel Esteller

Papers from R. Jenkins's perspective

Ordered by how strongly the researchers R. Jenkins trusts endorse each paper. Same corpus, a different order for every researcher.

1. An Integrated Genomic Analysis of Human Glioblastoma Multiforme (Science)
2. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (Cancer Cell)
3. MGMT gene silencing and benefit from temozolomide in glioblastoma. (New England Journal of Medicine)
4. IDH1 and IDH2 mutations in gliomas. (New England Journal of Medicine)
5. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized… (Journal of Clinical Oncology)
6. Genetic pathways to primary and secondary glioblastoma. (American Journal of Pathology)
7. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. (New England Journal of Medicine)
8. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. (American Journal of Pathology)
9. IDH mutation impairs histone demethylation and results in a block to cell differentiation (Nature)
10. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. (Journal of Clinical Oncology)

Their papers

• The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. (2013) — 639 citations
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. (2005) — 711 citations
• The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex (2013) — 677 citations
• Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors (2015) — 1,799 citations
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. (2013) — 1,051 citations
• A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. (2006) — 723 citations
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) — 1,382 citations
• cIMPACT-NOW Update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) — 744 citations
• The Estrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer (2014) — 604 citations
• Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy (2013) — 661 citations
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors (2013) — 1,308 citations
• Genetics of adult glioma. (2012) — 870 citations
• Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. (2006) — 698 citations
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) — 5,515 citations
• Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. (2000) — 809 citations